Given that the primary therapeutic mechanism for a selective estrogen receptor degrader (such as fulvestrant) in ER+ breast cancer is the induction of ERα degradation in a proteasome-dependent manner, we next assessed whether the combination L30I40 induced rapid ERα protein decreasing via ERα degradation. Here, ESR1 is linked to breast cancer.